Melanie Wayne
Family · Eugene, ORNPI 1912353657
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by CSL Behring at 37.4% of the total. Reporting peaked in 2023 at $3,133 and has fallen 83.6% since, to $514 in 2025. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $47.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- LEO Pharma Inc.$1K
- AstraZeneca$661
- GSK$336
- Sanofi$263
- Blueprint Medicines Corporation$248
- plus $1K from 17 others
What the payments were for
- Consulting fees$2,81944%
- Travel & lodging$4527%
- Food & beverage$3,05848%
- Education$992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 16 | $2,402 |
| LEO Pharma Inc. | 2 | $1,191 |
| AstraZeneca | 21 | $661 |
| GSK | 20 | $336 |
| Sanofi | 10 | $263 |
| Blueprint Medicines Corporation | 6 | $248 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $211 |
| Biocryst US Sales Co., LLC | 7 | $203 |
| Regeneron Healthcare Solutions, Inc. | 4 | $135 |
| Amgen(2 entities) | 5 | $99 |
| Novartis | 5 | $95 |
| Alk-abello, Inc | 2 | $83 |
| ADMA Biomanufacturing LLC | 3 | $79 |
| Genentech USA, Inc. | 8 | $78 |
| Pfizer | 4 | $69 |
| Grifols USA, LLC | 3 | $65 |
| Mylan Specialty L.p. | 3 | $46 |
| AbbVie | 2 | $35 |
| Octapharma USA, Inc. | 2 | $33 |
| Pharming Healthcare, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $31 |
| Tersera Therapeutics LLC | 1 | $20 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,429 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 25 | $937,641 |
| Dupixent SyringeDupilumab | 42 | $149,987 |
| Dupixent PenDupilumab | 26 | $146,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $124,700 |
| Spiriva RespimatTiotropium Bromide | 79 | $42,722 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $26,280 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $26,103 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 105 | $18,979 |
| Qvar RedihalerBeclomethasone Dipropionate | 55 | $16,524 |
| Fluticasone Propionate HfaFluticasone Propionate | 46 | $15,214 |
| Arnuity ElliptaFluticasone Furoate | 41 | $15,095 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $12,675 |
| Cromolyn Sodium | 31 | $10,238 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $8,178 |
| DuleraMometasone/Formoterol | 20 | $7,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $211 | $937,64125 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $336 | $165,898225 claims |
| Boehringer IngelheimSpiriva Respimat | $31 | $42,72279 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $661 | $38,95581 claims |
| MerckDulera, Asmanex | $15 | $10,86334 claims |
| Alk-abello, IncGrastek | $83 | $5,54311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Eugene
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
- Leah WessenbergPortland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.